Shalby Limited — Important, 03-02-2025: Financial Result Updates

**Consolidated Financial Results Summary**

Shalby Limited reported consolidated revenue from operations of ₹2,756.33 crore for the quarter ended December 31, 2024, reflecting a growth of approximately 27.57% over ₹2,160.47 crore for the same quarter last year. This growth can be attributed to an increase in patient volumes and the expansion of healthcare services, including the recent launch of India's largest Tissue and Bone Bank.

The net profit for the quarter stood at a loss of ₹29.93 crore, compared to a profit of ₹190.64 crore in Q3 FY2024. The decline in profitability is mainly due to higher operational costs, amounting to ₹2,687.01 crore, up from ₹1,897.55 crore in the same previous quarter. Significant increases were noted in employee benefits and operational expenses, reflecting strategic investments aimed at expanding service capabilities.

Shalby's balance sheet remains stable, with total assets rising to ₹17,910.10 crore while total liabilities decreased to ₹12,313.37 crore, indicating a healthy debt-to-equity ratio. The company continues to maintain a robust cash flow, supporting ongoing capital expenditures and operational investments.

Strategically, Shalby is focused on innovation in healthcare delivery and expanding its services internationally, which may improve market positioning in the long run.

For investors, despite the quarterly loss, the growth in revenue and strategic initiatives suggest a hold position as the company works towards achieving operational efficiencies and market expansion.